News – Page 1158 – Endpoints News

CRISPR upstart Casebia picks Sanofi vet Burns as new CEO; On the heels of a trial debacle, Opexa sheds staffers

9 years ago

Buffeted by safety fears, Cempra shares crushed after FDA flags a warning on its antibiotic

9 years ago

Oncolytic contender Turnstone bags a $41M B round to push a successor for Imlygic

9 years ago

On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders

9 years ago

Still pondering an M&A move, Gilead's R&D team outlines a Q3 lineup of setbacks on 3 pipeline drugs

9 years ago

AveXis shares soar after it outlines FDA’s support for a looming pivotal study on SMA

9 years ago

Post-PhIII implosion, Celldex buys oncology drug developer Kolltan in $235M deal

9 years ago

Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial

9 years ago

Bon appetit: Cellectis CEO Choulika hosts a gene-edited feast; CRO Medpace adding 650 staffers

9 years ago

Shire prunes Sanfilippo A drug after a failed PhIIb

9 years ago

SEC wants to sanction a PwC accountant for failing to flag Steven Burrill as he looted a biotech fund

9 years ago

MicroRNA player MiRagen bags $40M round and a public stock listing in reverse merger

9 years ago

Pfizer dumps a fading pipeline star, giving up on its PCSK9 drug bococizumab

9 years ago

Novartis’s blockbuster CDK 4/6 contender LEE011 gets a VIP countdown at the FDA

9 years ago

VIP Clinton supporter pitched campaign chief Podesta on Canadian price controls for the US

9 years ago

What’s on Sanofi’s M&A list now that Medivation is gone? Catalyst gets an SPA; Adaptimmune partners with Merck

9 years ago

NYC’s top research institutions partner on Step 2 in building a biotech hub

9 years ago

2016's drug pricing headwinds threaten a hurricane of new regulations

9 years ago

After a series of PI3k pileups, Genentech offloads a PhII-ready rival for firesale price

9 years ago

AstraZeneca R&D leader Pangalos warns of a post-Brexit UK research retreat without reimbursement reform

9 years ago

Influential Third Rock Ventures marks a decade of high-profile wins and losses with record $616M Fund IV

9 years ago

Manufacturing woes derail a blockbuster contender from Sanofi/Regeneron. Who's next?

9 years ago

Prominent MIT scientist Susan Lindquist dies of cancer; Election fears damaging biotech stocks?; Promethera adds 10M ...

9 years ago

Another Ramaswamy stunt plays well on Wall Street, Martin Shkreli on shame, and more

9 years ago

First page Previous page 1155 1156 115711581159 1160 1161 Next page Last page